Nitrogen containing heteroaromatics as factor Xa inhibitors
申请人:DuPont Pharmaceuticals Company
公开号:US06020357A1
公开(公告)日:2000-02-01
The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: ##STR1## or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(.dbd.NH)NH.sub.2, which are useful as inhibitors of factor Xa.
Eight imidazole alkaloids were isolated from Cynometra lujae: anantine, noranantine, cynometrine, isoanantine, isocynométrine, isocynodine, hydroxyanantine and cynolujine. The syntheses of isoanatine and isocynometrine were achieved starting from 1-methyl-5-methoxycarbonyl-imidazole and those of anantine and cynometrine starting from 1-methyl-4-methoxycarbonyl imidazole.
[EN] ION CHANNEL MODULATORS<br/>[FR] MODULATEURS DE LA FONCTION CANAL IONIQUE
申请人:SCION PHARMACEUTICALS INC
公开号:WO2005087748A1
公开(公告)日:2005-09-22
The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.
Preparation and use of imidazole derivatives for treatment of obesity
申请人:Smith A. Roger
公开号:US20050256167A1
公开(公告)日:2005-11-17
This invention relates to substituted imidazole derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders.
Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
申请人:——
公开号:US20040176400A1
公开(公告)日:2004-09-09
The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof wherein the variables are as defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).
1